Webinar | April 25, 2024

AAV Analytics: Key Considerations When Developing A Clinical Program

Inadequate analytical development and process validation pose significant challenges for advanced therapies, particularly AAV gene therapies. At Andelyn, we prioritize method validation throughout our development and manufacturing pipelines. As production scales, rigorous adaptation and development of research-derived assays ensure compliance with Good Manufacturing Practice (GMP) standards for plasmid and viral vector production.

Recognizing the critical need for product comparability over time, our dedicated quality control team meticulously executes GMP-compliant analytics for clinical-phase production. These efforts not only guarantee consistency in workflows, reagents, and processes but also ensure that assays meet stringent regulatory requirements and deliver reliable data throughout the manufacturing process.

Finding expert partners with the necessary skills to optimize AAV processes is crucial for minimizing variability and risk. Join Andelyn's webinar to explore key considerations for advancing your AAV gene therapy from concept to commercialization, leveraging the power of advanced analytics.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene